Abstract 271P
Background
High grade B cell lymphomas (HGBCL) are aggressive lymphomas, grouped into two entities according to whether or not they express double hit/double expresser phenotype. Entity without double hit/expresser phenotype is termed as HGBCL NOS. Best therapeutic approach to patients with HGBCL NOS is not known; treated with either regimens ideal for DLBCL or with more intensive Burkitt’s like regimens.
Methods
Hospital records of patients diagnosed with HGBCL NOS were retrieved. 34 patients had been non randomly assigned to receive CHOP like regimens (CHOP [20], COP [2], CHOP+HD MTX [5]) or dose adjusted (DA) EPOCH [7] with or without Rituximab[13]. Response rate (RR) to chemoimmunotherapy, toxicity profiles, PFS at 20 months of follow up and OS were noted.
Results
76.4 %(26) were diagnosed with advanced stage. 76.4%(26) had extra-nodal involvement. overall RR to first line therapy was 100%( CR = 58.8%, PR = 29.4%, SD = 11.8%). 48.1% CR and 37.0% PR in the CHOP like regimen arm and 100% CR rate in patients receiving DAEPOCH. At 20 months follow up, the mean and median PFS was 14.8 months and 11 months. DAEPOCH was associated with highest mean and median PFS (23.7 and 30 months) and same for CHOP were (10.31 and 9 months) at 20months of follow up(p = 0.039). Median OS not reached at 20 months of follow up. Use of Rituximab was associated with improved median PFS (30m vs 10m; p = 0.038) at 20 months, in univariate analysis. On an average 1.54 episodes of grade 3-4 neutropenia and 0.65 episodes of febrile neutropenia occurred per patient. Corresponding values for DAEPOCH and CHOP like regimens were (3.7 , 1.5) and ( 0.92, 0.40). 2(5.88%)cases had treatment related death, one each in DAEPOCH(14.2%) and CHOP like regimen arm (3.7%) arm. 21(61.76%) patients relapsed at one year.
Conclusions
Regimens like CHOP or DAEPOCH with Rituximab has high response rates but substantial proportion of patients may relapse. Grade 3-4 neutropenia occurs more frequently with DAEPOCH than CHOP, but treatment related mortality is low for both the regimens. Good PS patients do tolerate intensive regimens. Intensive regimens may be associated with longer PFS that may lead to longer OS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract